Login Register Cart 0
Generic placeholder image

Current Neurovascular Research

Editor-in-Chief

ISSN (Print): 1567-2026
ISSN (Online): 1875-5739

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Creation of Retinal Vein Occlusion Model in Cynomolgus Monkeys and Determination of its Pathological Features

Author(s): Satoshi Inagaki, Masamitsu Shimazawa*, Wataru Otsu, Tomoaki Araki, Yosuke Numata, Shinsuke Nakamura, Hideshi Tsusaki and Hideaki Hara

Volume 18, Issue 1, 2021

Published on: 31 August, 2020

Page: [123 - 133] Pages: 11

DOI: 10.2174/1567202617999200831151118

Price: $65

Abstract

Objective: A retinal vein occlusion (RVO) is a relatively common retinal vascular disorder, especially in the elderly. Many experiments have been performed on patients with an RVO but performing any type of experiments and especially longitudinal experiments on humans is difficult, if not impossible, on ethical grounds. Therefore, we have created a retinal vein occlusion (RVO) model by laser irradiation of cynomolgus monkeys after intravenous injection of rose bengal. We evaluated the pathological changes of the retina, and the effects of ranibizumab, an anti-vascular endothelial growth factor (VEGF) antibody, on the characteristics of the RVO.

Methods: The integrity of the vascular system was evaluated by fluorescein angiography (FA), and the retinal thickness and volume were determined by optical coherence tomography (OCT). The cytokines and growth factors in the aqueous humour were identified by multiplex profiling.

Results: Our results showed that ranibizumab decreased the degree of vascular leakage and retinal edema at 1-3 days (acute phase) and 3-7 days (subacute phase), and suppressed foveal thinning at 28-42 days (chronic phase) after the laser irradiation. Ranibizumab also decreased the area of the foveal avascular zone, and the area was negatively and significantly correlated with the thickness of the ganglion cell layer (GCL) complex. Furthermore, ranibizumab reduced the increased expression of VEGF in the aqueous humor, but did not affect the expressions of interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), angiopoietin-1 (ANG-1), or angiopoietin-2 (ANG-2). These findings suggest that ranibizumab attenuates the retinal edema and subsequent retinal atrophy in part by neutralizing VEGF. However, other cytokines and growth factors were also affected by the ranibizumab, which suggests that not only VEGF but also other unidentified agents might play a role in the pathogenesis of the RVO.

Conclusion: We have created a non-human primate RVO model, which resembles the clinical RVO pathology. In this model, an injection of ranibizumab leads to a reduction in vascular leakage and the retinal thickness and volume by blocking the expression of VEGF. Our model might be useful for investigating the pathological mechanisms of RVOs and explore new therapeutic agents for RVO.

Keywords: Ranibizumab, retinal vein occlusion (RVO), Non-human primate RVO model, retinal vascular disorder, VEGF, edema.

« Previous Next »
[1]
Rogers S, McIntosh RL, Cheung N, et al. International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117(2): 313-9.e1.
[http://dx.doi.org/10.1016/j.ophtha.2009.07.017] [PMID: 20022117]
[2]
Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140(2): 256-61.
[http://dx.doi.org/10.1016/j.ajo.2005.03.003] [PMID: 16086947]
[3]
Khayat M, Lois N, Williams M, Stitt AW. Animal Models of Retinal Vein Occlusion. Invest Ophthalmol Vis Sci 2017; 58(14): 6175-92.
[http://dx.doi.org/10.1167/iovs.17-22788] [PMID: 29222552]
[4]
Zhao T, Lu Q, Tao Y, Liang XY, Wang K, Jiang YR. Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study. Mol Vis 2011; 17: 1044-55.
[PMID: 21552499]
[5]
Coscas G, Gaudric A. Natural course of nonaphakic cystoid macular edema. Surv Ophthalmol 1984; 28(Suppl.): 471-84.
[http://dx.doi.org/10.1016/0039-6257(84)90229-7] [PMID: 6463848]
[6]
Spooner K, Fraser-Bell S, Hong T, Chang A. Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion. Asia Pac J Ophthalmol (Phila) 2020; 9(1): 48-53.
[http://dx.doi.org/10.1097/01.APO.0000617924.11529.88] [PMID: 31990746]
[7]
Genevois O, Paques M, Simonutti M, et al. Microvascular remodeling after occlusion-recanalization of a branch retinal vein in rats. Invest Ophthalmol Vis Sci 2004; 45(2): 594-600.
[http://dx.doi.org/10.1167/iovs.03-0764] [PMID: 14744903]
[8]
Fuma S, Nishinaka A, Inoue Y, et al. A pharmacological approach in newly established retinal vein occlusion model. Sci Rep 2017; 7: 43509.
[http://dx.doi.org/10.1038/srep43509] [PMID: 28252108]
[9]
Hida Y, Nakamura S, Nishinaka A, Inoue Y, Shimazawa M, Hara H. Effects of ripasudil, a ROCK inhibitor, on retinal edema and nonperfusion area in a retinal vein occlusion murine model. J Pharmacol Sci 2018; 137(2): 129-36.
[http://dx.doi.org/10.1016/j.jphs.2018.06.010] [PMID: 29983234]
[10]
Nishinaka A, Fuma S, Inoue Y, Shimazawa M, Hara H. Effects of kallidinogenase on retinal edema and size of non-perfused areas in mice with retinal vein occlusion. J Pharmacol Sci 2017; 134(2): 86-92.
[http://dx.doi.org/10.1016/j.jphs.2017.05.003] [PMID: 28619445]
[11]
Nishinaka A, Inoue Y, Fuma S, et al. Pathophysiological Role of VEGF on Retinal Edema and Nonperfused Areas in Mouse Eyes With Retinal Vein Occlusion. Invest Ophthalmol Vis Sci 2018; 59(11): 4701-13.
[http://dx.doi.org/10.1167/iovs.18-23994] [PMID: 30267092]
[12]
Nitta K, Nishinaka A, Hida Y, Nakamura S, Shimazawa M, Hara H. Oral and ocular administration of crocetin prevents retinal edema in a murine retinal vein occlusion model. Mol Vis 2019; 25: 859-68.
[PMID: 31908404]
[13]
Bringmann A, Reichenbach A, Wiedemann P. Pathomechanisms of cystoid macular edema. Ophthalmic Res 2004; 36(5): 241-9.
[http://dx.doi.org/10.1159/000081203] [PMID: 15583429]
[14]
Rotsos TG, Moschos MM. Cystoid macular edema. Clin Ophthalmol 2008; 2(4): 919-30.
[http://dx.doi.org/10.2147/OPTH.S4033] [PMID: 19668445]
[15]
Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator Molecular therapy : the journal of the American Society of Gene Therapy 2008; 16(4): 791-9.
[16]
Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 2013; (1): CD009510.
[http://dx.doi.org/10.1002/14651858.CD009510.pub2] [PMID: 23440840]
[17]
Hamilton AM, Kohner EM, Rosen D, Bird AC, Dollery CT. Experimental retinal branch vein occlusion in rhesus monkeys. I. Clinical appearances. Br J Ophthalmol 1979; 63(6): 377-87.
[http://dx.doi.org/10.1136/bjo.63.6.377] [PMID: 111701]
[18]
Rosen DA, Marshall J, Kohner EM, Hamilton AM, Dollery CT. Experimental retinal branch vein occlusion in rhesus monkeys. II. Retinal blood flow studies. Br J Ophthalmol 1979; 63(6): 388-92.
[http://dx.doi.org/10.1136/bjo.63.6.388] [PMID: 111702]
[19]
Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145(3): 574-84.
[PMID: 7521577]
[20]
Parodi MB, Visintin F, Della Rupe P, Ravalico G. Foveal avascular zone in macular branch retinal vein occlusion. Int Ophthalmol 1995; 19(1): 25-8.
[http://dx.doi.org/10.1007/BF00156415] [PMID: 8537192]

Rights & Permissions Print Cite
Article Metrics
52
© 2024 Bentham Science Publishers | Privacy Policy